Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study.

被引：0
|
作者：
Iqbal, S
Cole, S
Yang, D
Lara, PN
Gumerlock, PH
Shibata, S
Synold, T
Doroshow, JH
Gandara, D
Lenz, HJ
机构：
[1] Univ So Calif, Los Angeles, CA USA
[2] Univ Calif Davis, Sacramento, CA USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2057
引用
收藏
页码：141S / 141S
页数：1
相关论文
共 50 条
  • [1] A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies
    Fisher, GA
    Cho, CD
    Halsey, JZ
    Advani, RH
    Yuen, AR
    Lum, BL
    Sikic, BI
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S63 - S63
  • [2] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [3] Trimetrexate (TMTX) modulation of 5-fluorouracil leucovorin (5-FU/LV) for advanced colorectal cancer
    Blanke, C
    Kasimis, B
    Schein, P
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 748 - 748
  • [4] Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors.
    Hegeman, RB
    Mulkerin, D
    Thomas, J
    Alberti, D
    Binger, K
    Marnocha, R
    Kolesar, J
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 149S - 149S
  • [5] Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer
    Tsavaris, N
    Kosmas, C
    Gennatas, K
    Vadiaka, M
    Skopelitis, E
    Xila, V
    Rokana, S
    Margaris, E
    Zografos, G
    Papastratis, G
    Kouraklis, G
    JOURNAL OF CHEMOTHERAPY, 2002, 14 (04) : 406 - 411
  • [6] Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC).
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Bernuzzi, P
    Bertè, R
    Bidin, L
    Palladino, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 330S - 330S
  • [7] Phase II trial of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for advanced biliary tract adenocarcinoma.
    Porschen, R
    Nehls, O
    Bermann, A
    Burkart, C
    Gregor, M
    GASTROENTEROLOGY, 1999, 116 (04) : A487 - A487
  • [8] Palliative therapy for advanced biliary tract carcinoma with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV).
    Nehis, O
    Klump, B
    Gregor, M
    Porschen, R
    GASTROENTEROLOGY, 2000, 118 (04) : A523 - A523
  • [9] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in previously treated patients with advanced metastatic gastric cancer
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Anselmi, E
    Bidin, L
    Palladino, M
    Rodinò, C
    ANNALS OF ONCOLOGY, 2005, 16 : 323 - 323
  • [10] A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors
    Jordan D. Berlin
    Dona B. Alberti
    Rhoda Z. Arzoomanian
    Chris A. Feierabend
    Kris J. Simon
    Kim A. Binger
    Rebecca M. Marnocha
    George Wilding
    Investigational New Drugs, 1998, 16 : 325 - 330
12345